A compound identical to a natural brain cell precursor, sold as a nootropic. Its most solid and recent trials involve stroke and traumatic brain injury, not the memory of a healthy person.
“Strong” = several concordant meta-analyses or systematic reviews. “Moderate” = one synthesis, or several controlled trials. “Limited” = early trials only. The rating is about the quality of the studies, not about how useful the supplement is.
HowToGym · Unsplash
Clinical trials use 500 to 2000 mg per day, under medical supervision (stroke, traumatic brain injury, glaucoma). No dosage regimen exists for lifestyle use in a healthy person.
Well tolerated in all trials, with no serious side effects reported. Above all: the largest and most recent trials are negative. In over 1200 patients who suffered a traumatic brain injury, the COBRIT trial found no difference between citicoline and placebo on functional and cognitive recovery at 90 and 180 days. In over 2000 patients who suffered an ischemic stroke, the international ICTUS trial also found no difference in recovery at 90 days. An earlier phase III trial, on nearly 900 patients, showed no significant difference on its primary endpoint. Finally, and this is the most important point for the use sold in supplements: none of the studies reviewed here involve a healthy person looking to improve their memory or concentration. All available literature concerns patients who suffered a stroke, traumatic brain injury or glaucoma, under medical supervision — nothing documents the daily "nootropic" use for which citicoline is sold as a dietary supplement.
One might think that citicoline is a complex synthetic drug, but it is actually a substance identical to a natural precursor already present in our cells, which simply breaks down into choline and cytidine before being reused by the brain.
This large-scale international trial (ICTUS) tested citicoline (intravenous then oral, up to 2000 mg/day) in over 2000 patients who suffered a moderate-to-severe ischemic stroke. After 90 days, no significant difference in recovery was observed between the citicoline group and the placebo group. The study concludes that, under these conditions, citicoline did not demonstrate efficacy in treating acute ischemic stroke.
Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, Serena J, Segura T, Cruz VT, Masjuan J, Cobo E, Secades JJ, International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. — Lancet (London, England) (2012) — View the source study
For information only: not a substitute for medical advice. Dietary supplements are not a replacement for a varied, balanced diet. Learn more